Too Much, Too Little, Too Late to Start Again? Assessing the Efficacy of Bisphosphonates in Patients with Bone Metastases from Breast Cancer
TEST_code
|
CME Activity Information |
|
Release Date: |
March 20, 2006 |
|
Most Recent Review: |
May 8, 2007* |
|
Most Recent Update: |
March 20, 2006 |
|
Date Credit Expires: |
March 20, 2008 |
|
Time to Complete: |
1 hour |
|
Medium: |
Internet Online |
|
*Click here
to learn more about our review process. |
Instructions for Participation
- Read the following information before beginning the educational activity
and click the "Take this course" link at the bottom of the page
- Study the educational activity
- Complete the CME quiz and evaluation
- After successful completion of the CME quiz and evaluation, you will receive
the credit or participation certificate
*The CME quiz and evaluation must be completed by March 20, 2008, in order
to receive the credit or participation certificate.
Target Audience
Physicians who wish to advance their current knowledge of clinical cancer medicine
in breast cancer and are involved in providing patient care in a cancer care environment.
Learning Objectives
After completing this course, the reader should be able to:
- Articulate the natural history of bone metastasis in the setting of advanced
breast cancer.
- Describe the role of bisphosphonates in managing bone metastases in the
setting of breast cancer.
- Discuss clinical end points used to determine whether bisphosphonates are
useful in this setting.
Accreditation and Credit Designation
This activity has been planned and implemented in accordance
with the Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of the National Institutes
of Health Foundation for Advance Education in the Sciences (NIH/FAES) and The
Oncologist. The NIH/FAES is accredited by the ACCME to provide continuing
medical education for physicians.
The NIH/FAES designates this educational activity for a maximum of 1.00 AMA
PRA Category 1 Credit™. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
Disclosure Policy
In compliance with the Standards of the ACCME, it is the policy of the NIH/FAES to ensure balance,
independence, objectivity, and scientific rigor in all of its educational activities
and to include information free of commercial bias and based on the best evidence
available. All individuals in a position to influence the content of this activity
have disclosed relevant financial interests or relationships of their own, their
spouse/partner, or their worksite, with manufacturers or providers of commercial
products, services, technology, or programs; and disclosed relationships with
current non-governmental supporters of the activity. The faculty and planners
have indicated that they have no relevant commercial relationships. For a list
of the faculty and planners, please visit the Editorial Board online at http://cme.theoncologist.com/misc/edboard.shtml.
All information is submitted and reviewed and found to be scientifically rigorous,
based on the best available evidence, fair and balanced, and free of commercial
bias. All the recommendations involving clinical medicine in this CME activity
are based on evidence that is accepted within the profession of medicine as
adequate justification for their indications and contraindications in the care
of patients. All scientific research referred to, reported or used in CME in
support or justification of a patient care recommendation conforms to the generally
accepted standards of experimental design, data collection and analysis.
Any potential conflicts of interests are resolved via The Oncologist's
anonymous peer review process: http://theoncologist.alphamedpress.org/misc/ifora.shtml.
All manuscripts are reviewed by the Editorial Board with ad hoc assistance from
two or more external experts in the field. All final publication decisions are
made by the Editorial Board. The acceptance of a manuscript is based on its
originality and importance to the field as assessed by the Editors.
Author Disclosure(s)
Mark Clemons, M.D.
Credentials: Division of Medical Oncology, Sunnybrook and
Women’s College Health Sciences Centre, Toronto, Canada. Telephone:
416-480-5847; Fax: 416-480-6002; E-mail: mark.clemons{at}sw.ca.
Disclosures: The author has received research funding and
financial support from Roche and Novartis.
George Dranitsaris, M.Pharm., F.C.S.H.P.
Credentials: Cancer Care Ontario, Toronto, Canada.
Disclosures: The author has received honorarium from Novartis.
David Cole, M.D.
Credentials: Department of Clinical Pathology, Sunnybrook
and Women’s College Health Sciences Centre, Toronto, Canada.
Disclosures: The author has indicated no relevant commercial
relationships.
Mary C. Gainford, M.D.
Credentials: Division of Medical Oncology, Sunnybrook and
Women’s College Health Sciences Centre, Toronto, Canada.
Disclosures: The author has indicated no relevant commercial
relationships.
Commercial Support
Non-governmental supporters of this activity: Bristol-Myers
Squibb Oncology and sanofi-aventis
Hardware/Software Requirements
The Oncologist CME Online supports
the following browsers: Current production versions of Opera, Safari, Firefox,
Lynx and Mozilla; Netscape 6.1 and above, and Explorer 6.0 and above. The Macintosh
version of Explorer was discontinued in June 2003, and is not supported.
Other Links
Disclaimer
Privacy statement
Correspondence
The Oncologist CME Online
c/o AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email: angela.davies{at}ucdmc.ucdavis.edu
View this course
EXPIRED
Copyright © 2008 by AlphaMed Press.